FOGHORN THERAPEUTICS I
7.8300
07-October-24 11:13:54
15 minutes delayed
Stocks
0.0000
0.00%
Today's range
7.5000 - 7.9100
ISIN
N/A
Source
NASDAQ
-
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
14 Nov 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
08 Nov 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
27 Oct 2022 06:00:01 By Nasdaq GlobeNewswire
-
26 Oct 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
20 Oct 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
27 Sep 2022 07:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
01 Sep 2022 15:05:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Announces Change to Board of Directors
31 Aug 2022 15:05:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
23 Aug 2022 06:00:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
17 Aug 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
09 Aug 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
31 May 2022 15:05:00 By Nasdaq GlobeNewswire
-
19 May 2022 15:01:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides First Quarter 2022 Corporate Update
09 May 2022 06:00:01 By Nasdaq GlobeNewswire
-
13 Apr 2022 10:30:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting
01 Apr 2022 07:00:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day
11 Mar 2022 15:01:00 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook
10 Mar 2022 06:00:01 By Nasdaq GlobeNewswire
-
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire